A Hemoadsorptive Device for the Treatment of SIRS

Information

  • Research Project
  • 6789079
  • ApplicationId
    6789079
  • Core Project Number
    R41GM069127
  • Full Project Number
    1R41GM069127-01A1
  • Serial Number
    69127
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/13/2004 - 19 years ago
  • Project End Date
    9/12/2005 - 18 years ago
  • Program Officer Name
    SOMERS, SCOTT D.
  • Budget Start Date
    9/13/2004 - 19 years ago
  • Budget End Date
    9/12/2005 - 18 years ago
  • Fiscal Year
    2004
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    9/13/2004 - 19 years ago

A Hemoadsorptive Device for the Treatment of SIRS

[unreadable] DESCRIPTION (provided by applicant): [unreadable] The overall objective of the proposed project is to develop a hemoperfusion device for the clinical treatment of sepsis and other conditions related to the Systemic Inflammatory Response Syndrome (SIRS). RenalTech International and Dr. John Kellum of the University of Pittsburgh have completed promising in vitro and in vivo laboratory studies in several models of acute sepsis using a new polymer in a packed bead column device for hemoadsorption. These studies indicate that the polymer efficiently removes cytokines from whole blood, causes significant and beneficial modulation of the inflammatory response and improves survival time in a lethal animal model of sepsis. These data strongly suggest that this treatment may be beneficial to patients with sepsis and related SIRS conditions. However, before hemoadsorption can be used in clinical trials with critically ill patients, several important tasks must be achieved. The Phase I objectives of this project will determine optimal system characteristics for removal of several representative molecules from whole blood. The ultimate goal of Phase I will be to establish the optimal specifications for the adsorbent polymer, the device containing the polymer, the physical or chemical conditions and clinical parameters so that pilot human clinical trials in patients with SIRS can be designed. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R41
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MEDASORB TECHNOLOGIES, LLC
  • Organization Department
  • Organization DUNS
  • Organization City
    MONMOUTH JUNCTION
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    08862
  • Organization District
    UNITED STATES